Analysts Set Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Price Target at $55.40

Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) have earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $55.40.

Separately, Oppenheimer cut their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Friday, August 14th.

Pelthos Therapeutics Trading Up 0.8%

NYSEAMERICAN:PTHS opened at $25.03 on Friday. The stock has a fifty day simple moving average of $26.90 and a 200 day simple moving average of $25.34. The firm has a market capitalization of $95.86 million, a price-to-earnings ratio of -1.14 and a beta of 3.01. Pelthos Therapeutics has a 1-year low of $18.19 and a 1-year high of $37.50. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. The firm had revenue of $15.60 million for the quarter. Sell-side analysts forecast that Pelthos Therapeutics will post -15.22 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Todd C. Davis bought 35,948 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the purchase, the director directly owned 75,834 shares in the company, valued at $2,109,701.88. This trade represents a 90.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 1,638 shares of company stock worth $43,107. Insiders own 16.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PTHS. Geode Capital Management LLC lifted its stake in Pelthos Therapeutics by 31.9% in the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after acquiring an additional 3,295 shares in the last quarter. Knott David M Jr lifted its position in shares of Pelthos Therapeutics by 215.5% in the fourth quarter. Knott David M Jr now owns 19,281 shares of the company’s stock worth $598,000 after purchasing an additional 13,169 shares in the last quarter. Persistent Asset Partners Ltd lifted its position in shares of Pelthos Therapeutics by 150.0% in the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after purchasing an additional 3,604 shares in the last quarter. Diadema Partners LP boosted its holdings in shares of Pelthos Therapeutics by 138.1% during the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after purchasing an additional 14,502 shares during the period. Finally, Cantor Fitzgerald L. P. acquired a new stake in shares of Pelthos Therapeutics during the fourth quarter worth approximately $1,085,000. 77.96% of the stock is owned by institutional investors and hedge funds.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).